B7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma)

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameB7-H3 CAR-T cell therapy (Boyuan Runsheng Pharma)
Drug Alias NameB7-H3 CAR-T细胞疗法-浙江大学
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived +[4] 
Mechanisms of ActionCD276 antigen inhibitorsT lymphocyte replacements
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumoursGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBoyuan Runsheng Pharma (Hangzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBoyuan Runsheng Pharma (Hangzhou) Co LtdSt. Jude Children'S Research Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumoursGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A